

Michael B Boffa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7760750/publications.pdf>

Version: 2024-02-01

87
papers

4,021
citations

136740

32
h-index

118652

62
g-index

87
all docs

87
docs citations

87
times ranked

3169
citing authors

#	ARTICLE	IF	CITATIONS
1	A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor. <i>Journal of Biological Chemistry</i> , 1998, 273, 27176-27181.	1.6	329
2	Thrombin, Thrombomodulin and TAFI in the Molecular Link Between Coagulation and Fibrinolysis. <i>Thrombosis and Haemostasis</i> , 1997, 78, 386-391.	1.8	223
3	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. <i>Circulation</i> , 2019, 139, 1472-1482.	1.6	196
4	Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?. <i>Journal of Lipid Research</i> , 2016, 57, 745-757.	2.0	181
5	Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. <i>Journal of Biological Chemistry</i> , 2015, 290, 11649-11662.	1.6	176
6	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). <i>Journal of Lipid Research</i> , 2013, 54, 2815-2830.	2.0	174
7	Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties. <i>Journal of Biological Chemistry</i> , 1998, 273, 2127-2135.	1.6	167
8	Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 305-318.	6.1	158
9	Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme. <i>Journal of Biological Chemistry</i> , 2002, 277, 1021-1030.	1.6	148
10	Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. <i>Clinical Biochemistry</i> , 2004, 37, 333-343.	0.8	134
11	Subclinical Vitamin K Deficiency in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2007, 49, 432-439.	2.1	122
12	A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. <i>Blood</i> , 2001, 98, 1992-1993.	0.6	112
13	Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor. <i>Journal of Biological Chemistry</i> , 2000, 275, 12868-12878.	1.6	99
14	Inhibition of Plasminogen Activation by Lipoprotein(a). <i>Journal of Biological Chemistry</i> , 2003, 278, 23260-23269.	1.6	99
15	Lipoprotein(a). <i>Current Opinion in Lipidology</i> , 2012, 23, 133-140.	1.2	99
16	Lipoprotein(a): A Unique Risk Factor for Cardiovascular Disease. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 751-772.	0.7	86
17	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). <i>Journal of Lipid Research</i> , 2015, 56, 2273-2285.	2.0	85
18	Characterization of the Gene Encoding Human TAFI (Thrombin-Activable Fibrinolysis Inhibitor; Plasma) Tj ETQqO 0 0,rgBT /Overlock 10 T	1.2	84

#	ARTICLE	IF	CITATIONS
19	Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. <i>Clinical Biochemistry</i> , 2007, 40, 431-442.	0.8	84
20	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. <i>Progress in Lipid Research</i> , 2017, 68, 57-82.	5.3	63
21	The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 6526-6533.	1.6	55
22	Association of a single nucleotide polymorphism in CPB2 encoding the thrombin-activable fibrinolysis inhibitor (TAFI) with blood pressure. <i>Clinical Genetics</i> , 2001, 60, 345-349.	1.0	52
23	Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). <i>Journal of Lipid Research</i> , 2014, 55, 625-634.	2.0	52
24	The Solution Phase Interaction between Apolipoprotein(a) and Plasminogen Inhibits the Binding of Plasminogen to a Plasmin-Modified Fibrinogen Surface. <i>Biochemistry</i> , 1997, 36, 10353-10363.	1.2	50
25	Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 9250-9257.	1.6	46
26	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2113-2120.	1.9	46
27	Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. <i>Blood</i> , 2008, 111, 183-189.	0.6	42
28	Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a). <i>Clinical Chemistry</i> , 2021, 67, 490-499.	1.5	40
29	Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. <i>PLoS ONE</i> , 2017, 12, e0180869.	1.1	40
30	New Frontiers in Lp(a)-Targeted Therapies. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 212-225.	4.0	39
31	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. <i>Journal of Lipid Research</i> , 2019, 60, 2082-2089.	2.0	35
32	Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2523-2529.	1.9	34
33	Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator. <i>Current Atherosclerosis Reports</i> , 2013, 15, 360.	2.0	32
34	Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. <i>Atherosclerosis</i> , 2022, 349, 92-100.	0.4	31
35	Role of mRNA transcript stability in modulation of expression of the gene encoding thrombin activable fibrinolysis inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1969-1979.	1.9	30
36	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1358-1366.	0.6	30

#	ARTICLE	IF	CITATIONS
37	Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. <i>Atherosclerosis</i> , 2022, 349, 72-81.	0.4	30
38	Stimulation of Vascular Smooth Muscle Cell Proliferation and Migration by Apolipoprotein(a) Is Dependent on Inhibition of Transforming Growth Factor- β Activation and on the Presence of Kringle IV Type 9. <i>Journal of Biological Chemistry</i> , 2004, 279, 55187-55195.	1.6	27
39	Lipoprotein(a). <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 949-962.	1.2	27
40	Apolipoprotein(a) stimulates nuclear translocation of β -catenin: a novel pathogenic mechanism for lipoprotein(a). <i>Molecular Biology of the Cell</i> , 2013, 24, 210-221.	0.9	26
41	Apolipoprotein(a) Inhibits In Vitro Tube Formation in Endothelial Cells: Identification of Roles for Kringle V and the Plasminogen Activation System. <i>PLoS ONE</i> , 2013, 8, e52287.	1.1	23
42	A Role for CCAAT/Enhancer-binding Protein in Hepatic Expression of Thrombin-activable Fibrinolysis Inhibitor. <i>Journal of Biological Chemistry</i> , 2002, 277, 25329-25336.	1.6	22
43	Activated thrombin-activatable fibrinolysis inhibitor (TAFI) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis. <i>BMC Cancer</i> , 2016, 16, 328.	1.1	21
44	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 33-54.	2.7	20
45	IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer: The potential role of tumor infiltrated macrophages. <i>Current Problems in Cancer</i> , 2018, 42, 215-230.	1.0	18
46	Modulation of Fibrin Cofactor Activity in Plasminogen Activation. <i>Annals of the New York Academy of Sciences</i> , 2001, 936, 247-260.	1.8	17
47	Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 289-304.	1.1	17
48	Lipoprotein(a) as a therapeutic target in cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 747-757.	1.5	16
49	Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells. <i>Thrombosis and Haemostasis</i> , 2011, 105, 999-1009.	1.8	15
50	Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2020, 5, 888-897.	1.9	15
51	Baboon Lipoprotein(a) Binds Very Weakly to Lysine- β -Agarose and Fibrin Despite the Presence of a Strong Lysine-Binding Site in Apolipoprotein(a) Kringle IV Type 10. <i>Biochemistry</i> , 2005, 44, 555-564.	1.2	14
52	Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. <i>Metabolites</i> , 2021, 11, 459.	1.3	14
53	Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR. <i>Thrombosis and Haemostasis</i> , 2015, 114, 337-349.	1.8	13
54	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 305-311.	2.3	13

#	ARTICLE	IF	CITATIONS
55	Molecular analysis of the human thrombin-activatable fibrinolysis inhibitor gene promoter. <i>British Journal of Haematology</i> , 2007, 138, 231-244.	1.2	12
56	Functional analysis of mutant variants of thrombin-activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 665-672.	1.9	12
57	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 606-619.	0.7	12
58	Understanding the ins and outs of lipoprotein (a) metabolism. <i>Current Opinion in Lipidology</i> , 2022, 33, 185-192.	1.2	12
59	Screening for and Management of Elevated Lp(a). <i>Current Cardiology Reports</i> , 2013, 15, 417.	1.3	11
60	The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?. <i>Current Opinion in Lipidology</i> , 2018, 29, 259-267.	1.2	11
61	A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization. <i>CJC Open</i> , 2021, 3, 450-459.	0.7	11
62	Regulation of the gene encoding human thrombin-activatable fibrinolysis inhibitor by estrogen and progesterone. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 393-404.	0.5	10
63	Lipoprotein(a): lodestar for future clinical trials. <i>Lancet, The</i> , 2018, 392, 1281-1282.	6.3	10
64	Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 772-783.	1.9	9
65	Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2016, 18, 69.	2.0	9
66	A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation. <i>Archives of Biochemistry and Biophysics</i> , 2003, 412, 186-195.	1.4	8
67	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells. <i>Thrombosis Research</i> , 2018, 169, 1-7.	0.8	8
68	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). <i>Journal of Lipid Research</i> , 2020, 61, 1263-1270.	2.0	8
69	Regulation of the mouse gene encoding TAFI by TNF α : Role of NF κ B binding site. <i>Cytokine</i> , 2012, 57, 389-397.	1.4	7
70	The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity. <i>Thrombosis and Haemostasis</i> , 2013, 109, 1033-1044.	1.8	7
71	Simultaneous R ² and quantitative susceptibility mapping measurement enables differentiation of thrombus hematocrit and age: an in vitro study at 3 T. <i>Journal of NeuroInterventional Surgery</i> , 2019, 11, 1155-1161.	2.0	7
72	Therapeutic Lowering of Lipoprotein(a). <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002052.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins $\alpha 2$ and $\alpha 3$. <i>Atherosclerosis</i> , 2018, 275, 11-21.	0.4	6
74	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2019, 30, 428-437.	1.2	6
75	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). <i>Journal of Lipid Research</i> , 2022, 63, 100216.	2.0	4
76	Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 5'-untranslated region. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 887-894.	1.9	3
77	Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 155-169.	1.7	3
78	Lipoprotein(a) as an Emerging Risk Factor for Atherothrombosis. , 2007, , 241-266.		3
79	TAFI and wound healing: closing a knowledge gap. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2075-2077.	1.9	2
80	Genetics to the Rescue. <i>Journal of the American College of Cardiology</i> , 2021, 78, 450-452.	1.2	2
81	Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1600-1602.	1.9	1
82	Lipoprotein(a). , 2021, , 547-581.		0
83	Regulation of Human Thrombin-Activable Fibrinolysis Inhibitor Gene Expression in Megakaryocyte-Like (Dami) and Monocyte/Macrophage- Like (THP-1) Cell Lines. <i>Blood</i> , 2008, 112, 3078-3078.	0.6	0
84	Regulation of the Gene Encoding Human Thrombin-Activable Fibrinolysis Inhibitor by Female Sex Steroids. <i>Blood</i> , 2008, 112, 3077-3077.	0.6	0
85	Exon Skipping and Alternative Splicing of CPB2 mRNA in Multiple Cell Types Results in Variants of TAFI That Are Inactive and Not Secretable. <i>Blood</i> , 2011, 118, 1189-1189.	0.6	0
86	Apolipoprotein(a)-Dependent Inhibition of Pericellular Plasminogen Activation Is Mediated by Specific Cellular Receptors. <i>Blood</i> , 2011, 118, 2236-2236.	0.6	0
87	Lipoprotein (a): Principles from Bench to Bedside. <i>Contemporary Cardiology</i> , 2021, , 363-381.	0.0	0